PRA Health Sciences, Inc. (NASDAQ:PRAH) had its target price lifted by equities research analysts at Credit Suisse Group from $80.00 to $84.00 in a research note issued to investors on Tuesday. The brokerage currently has an “outperform” rating on the medical research company’s stock. Credit Suisse Group’s price target suggests a potential upside of 13.16% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Citigroup Inc. reaffirmed a “buy” rating and issued a $90.00 target price (up from $73.00) on shares of PRA Health Sciences in a research note on Wednesday, June 28th. Jefferies Group LLC boosted their price target on shares of PRA Health Sciences from $72.00 to $72.50 and gave the stock a “buy” rating in a research note on Friday, April 28th. Robert W. Baird boosted their price target on shares of PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday. BidaskClub downgraded shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Bank of America Corporation assumed coverage on shares of PRA Health Sciences in a research note on Monday, June 26th. They set a “buy” rating and a $89.00 price target for the company. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $75.25.

PRA Health Sciences (NASDAQ:PRAH) traded up 7.80% on Tuesday, hitting $80.02. 398,884 shares of the stock traded hands. The stock has a market cap of $5.00 billion, a P/E ratio of 47.80 and a beta of 0.45. The stock has a 50-day moving average price of $75.01 and a 200 day moving average price of $66.37. PRA Health Sciences has a 12-month low of $46.52 and a 12-month high of $80.99.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.72 by $0.10. PRA Health Sciences had a return on equity of 21.87% and a net margin of 5.85%. The company had revenue of $457.90 million during the quarter, compared to the consensus estimate of $447.79 million. During the same period in the prior year, the firm posted $0.63 earnings per share. The company’s revenue was up .5% on a year-over-year basis. On average, equities analysts expect that PRA Health Sciences will post $3.15 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “PRA Health Sciences, Inc. (NASDAQ:PRAH) Price Target Raised to $84.00” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/pra-health-sciences-inc-nasdaqprah-price-target-raised-to-84-00.html.

A number of hedge funds and other institutional investors have recently modified their holdings of PRAH. Old Mutual Global Investors UK Ltd. purchased a new position in shares of PRA Health Sciences during the first quarter worth about $7,105,000. Russell Investments Group Ltd. boosted its position in shares of PRA Health Sciences by 10.6% in the first quarter. Russell Investments Group Ltd. now owns 694,231 shares of the medical research company’s stock worth $45,286,000 after buying an additional 66,449 shares in the last quarter. Sawgrass Asset Management LLC boosted its position in shares of PRA Health Sciences by 57.0% in the first quarter. Sawgrass Asset Management LLC now owns 23,470 shares of the medical research company’s stock worth $1,531,000 after buying an additional 8,525 shares in the last quarter. Meritage Portfolio Management purchased a new position in shares of PRA Health Sciences during the first quarter worth about $4,527,000. Finally, Independent Portfolio Consultants Inc. purchased a new position in shares of PRA Health Sciences during the first quarter worth about $279,000.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.